Precursor lesions of ovarian epithelial malignancy
K M Feeley
Departments of Histopathology, Royal Hallamshire Hospital, Sheffield, and
Search for more papers by this authorK M Feeley
Departments of Histopathology, Royal Hallamshire Hospital, Sheffield, and
Search for more papers by this authorAbstract
Most ovarian carcinomas arise from the mesothelial surface lining of the ovaries, or from invaginations of this lining into the superficial ovarian cortex to form cortical inclusion cysts. The native ovarian surface mesothelium is of an ‘uncommitted’ phenotype, and has potential to modulate to epithelial or mesenchymal phenotypes in response to signals such as those associated with ovulation. The exposure of the mesothelial lining of an inclusion cyst to the ovarian stromal microenvironment may be responsible for the phenotypic change to Müllerian epithelium so commonly seen in these cysts. Müllerian metaplasia is usually to a serous phenotype, and it is possible that undefined molecular events occurring in an inclusion cyst that has undergone Müllerian metaplasia may initiate neoplastic change in these cysts. This may be the developmental pathway of most invasive serous carcinomas. Occasional rare cases of ovarian intraepithelial neoplasia, manifested by epithelial atypia in an inclusion cyst or on the surface epithelium without invasive carcinoma, are identified histologically. Serous borderline tumours represent a separate category and in most cases probably do not progress to frank carcinoma. Mucinous carcinomas may in some cases have arisen from pre-existing benign and borderline mucinous tumours. Endometriosis of the ovary is associated with genetic abnormalities and is frequently found in association with clear cell and endometrioid carcinomas, suggesting that in many cases these latter two types of carcinoma may have arisen directly from endometriotic deposits. Ovaries removed prophylactically from women with a family history of ovarian carcinoma or with a mutation in one of the genes predisposing to ovarian carcinoma should be processed in their entirety, and examined closely not just for obviously neoplastic lesions, but also for more subtle morphological abnormalities of the surface epithelium or the epithelium lining cortical inclusion cysts.
References
- 1
Scully RE,
Bell DA,
Abu-Jawdeh GM.
Update on early ovarian cancer and cancer developing in benign ovarian tumours. In: F Sharp,
P Mason,
T Blackett,
J. Berek eds.
Ovarian Cancer 3. London: Chapman & Hall Medical, 1995: 139 144.
10.1007/978-1-4757-0136-4_14 Google Scholar
- 2 Fearon E & Vogelstein B. A genetic model for colorectal tumorgenesis. Cell 1990; 61; 759 767.
- 3 Wells M & Hutson R. Candidate precursor lesions. In: F Sharp, T Blackett, R Leake, J. Berek eds. Ovarian Cancer 4. London: Chapman & Hall Medical, 1996: 27 35.
- 4 Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development. Cancer 1993; 71; 530 536.
- 5 Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol. Oncol. 1990; 38; 367 372.
- 6 Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma, A search for preneoplastic lesions. Int. J. Gynecol. Pathol. 1993; 12; 59 63.
- 7 Tresserra F, Grases PJ, Labastida R, Ubeda A. Histological features of the contralateral ovary in patients with unilateral ovarian cancer: a case control study. Gynecol. Oncol. 1998; 71; 437 441.DOI: 10.1006/gyno.1998.5185
- 8 Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumours. Obstet. Gynecol. 1993; 82; 181 186.
- 9 Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS, Paterson JM. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum. Pathol. 1999; 30; 151 157.
- 10 Salazar H, Godwin AK, Getts LA et al. Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer. In: F Sharp, P Mason, T Blackett, J. Berek eds. Ovarian Cancer 3. London: Chapman & Hall Medical, 1995: 145 156.
- 11 Auersperg N, Maines-Bandiera SL, Dyck HG et al. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab. Invest. 1994; 71; 510 518.
- 12 Czernobilsky B, Moll R, Levy R et al. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa, and rete ovarii cells of the human ovary. Eur. J. Cell Biol. 1985; 37; 175 190.
- 13 Siemens CH & Auersperg N. Serial propagation of human ovarian surface epithelium in tissue culture. J. Cell. Physiol. 1988; 134; 347 356.
- 14 Kruk PA, Uitto VJ, Firth JD et al. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp. Cell Res. 1994; 215; 97 108.DOI: 10.1006/excr.1994.1320
- 15 Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am. J. Obstet. Gynecol. 1992; 167; 729 735.
- 16 Auersperg N, Maines-Bandiera SL, Dyck HG. Phenotypic plasticity of ovarian surface epithelium: possible implications for ovarian carcinogenesis. In: F Sharp, T Blackett, R Leake, J. Berek eds. Ovarian Cancer 4. London: Chapman & Hall Medical, 1996: 3 17.
- 17 Hamilton TC, Young RC, McKoy WM et al. Characterization of a human ovarian carcinoma cell line (NIH. OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983; 43; 5379 5389.
- 18
Fogh J &
Tremple G.
New human tumour cell lines. In: J. Fogh eds.
Human Tumour Cell in Vitro. New York: Plenum, 1975: 115 160.
10.1007/978-1-4757-1647-4_5 Google Scholar
- 19
Dyck HG,
Hamilton TC,
Godwin AK,
Lynch HT,
Maines-Bandiera S,
Auersperg N.
Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer.
Int. J. Cancer
1996; 69; 429 436.DOI: 10.1002/(sici)1097-0215(19961220)69:6<429::aid-ijc1>3.0.co;2-6
10.1002/(sici)1097-0215(19961220)69:6<429::aid-ijc1>3.0.co;2-6 CAS PubMed Web of Science® Google Scholar
- 20
Auersperg N,
Maines-Bandiera SL,
Kruk PA.
Human ovarian surface epithelium: growth patterns and differentiation. In: F Sharp,
P Mason,
T Blackett,
J. Berek eds.
Ovarian Cancer 3. London: Chapman & Hall Medical, 1995: 157 169.
10.1007/978-1-4757-0136-4_16 Google Scholar
- 21 Rodriguez GC, Walmer DK, Cline M et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J. Soc. Gynecol. Investig. 1998; 5; 271 276.DOI: 10.1016/s1071-5576(98)00017-3
- 22 Fathalla MF. Incessant ovulation – a factor in ovarian neoplasia? Lancet 1971; 2 (7716); 163.
- 23 Scully RE. Pathology of ovarian cancer precursors. J. Cell. Biochem. 1995; 23 (Suppl.); 208 218.
- 24 Godwin A, Testa J, Handel L et al. Spontaneous transformation of rat ovarian surface epithelial cells implicates repeated ovulation in ovarian cancer etiology and is associated with clonal cytogenetic changes. J. Natl. Cancer Inst. 1992; 84; 592 601.
- 25 Deligdisch L. Ovarian dysplasia: a review. Int. J. Gynecol. Cancer 1997; 7; 89 94.
- 26 Kupryjanczyk J, Thor AD, Beauchamp R et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA. 1993; 90; 4961 4965.
- 27 Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995; 27; 367 371.
- 28 Dubeau L. The cell of origin of ovarian epithelial tumours and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol. Oncol. 1999; 72; 437 442.DOI: 10.1006/gyno.1998.5275
- 29 Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumours and stage I carcinomas. Hum. Pathol. 1995; 26; 387 392.
- 30 Klemi PJ, Takahashi S, Joensuu H et al. Immunochistochemical detection of p53 protein in borderline and malignant serous ovarian tumours. Int. J. Gynecol. Pathol. 1994; 13; 228 233.
- 31 Zheng J, Benedict WF, Xu HJ et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J. Natl. Cancer Inst. 1995; 87; 1146 1153.
- 32
Skomedal H,
Kristensen GB,
Abeler VM et al.
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
J. Pathol.
1997; 181; 158 165.DOI: 10.1002/(sici)1096-9896(199702)181:2<158::aid-path742>3.3.co;2-#
10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 33 Cheng PC, Goswehr JA, Kim TM et al. Potential role of the inactivated X chromosome in ovarian epithelial tumour development. J. Natl. Cancer Inst. 1996; 88; 510 518.
- 34 Tangir J, Loughridge NS, Berkowitz RS et al. Frequent microsatellite instability in epithelial borderline ovarian tumours. Cancer Res. 1996; 56; 2501 2505.
- 35 King BL, Carcangiu ML, Carter D et al. Microsatellite instability in ovarian neoplasms. Br. J. Cancer 1995; 72; 376 382.
- 36 Powell DE. Low malignant potential tumours of the ovary: does microinvasion matter? Hum. Pathol. 1996; 27; 517 518.
- 37
Evans MF,
McDicken IW,
Herrington CS.
Numerical abnormalities of chromosomes 1, 11, 17 and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
J. Pathol.
1999; 189; 53 59.DOI: 10.1002/(sici)1096-9896(199909)189:1<53::aid-path393>3.0.co;2-u
10.1002/(sici)1096-9896(199909)189:1<53::aid-path393>3.0.co;2-u CAS PubMed Web of Science® Google Scholar
- 38 Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L. Histologically benign or low-grade malignant tumours adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res. 1993; 53; 4138 4142.
- 39 Beck RP & Latour JP. A review of 1019 benign ovarian neoplasms. Obstet. Gynecol. 1960; 16; 479 482.
- 40 Russell P. The pathological assessment of ovarian neoplasms. 1: Introduction to the common ‘epithelial’ tumours and analysis of benign ‘epithelial’ tumours. Pathology 1979; 11; 5 26.
- 41 Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM, Frank TS. Comparison of mutations of Ki-ras and p53 immunoreactivity in borderline and malignant epithelial ovarian tumours. Am. J. Surg. Pathol. 1999; 23; 323 328.
- 42 Chi-Ho Mok S, Bell DA, Knapp RC et al. Mutation of K-ras Protooncogene in human ovarian epithelial tumours of borderline malignancy. Cancer Res. 1993; 53; 1489 1492.
- 43 Watson RH, Neville PJ, Roy WJ Jr, Hitchcock A, Campbell IG. Loss of heterozygosity of chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 1998; 17; 207 212.
- 44 Puls LE, Powell DE, DePriest PD et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol. Oncol. 1992; 47; 53 57.
- 45
Rutgers JL &
Scully RE.
Ovarian Müllerian papillary cystadenomas of borderline malignancy: a clinicopathologic analysis.
Cancer
1988; 61; 340 348.
10.1002/1097-0142(19880115)61:2<340::AID-CNCR2820610225>3.0.CO;2-U CAS PubMed Web of Science® Google Scholar
- 46 Russell P & Farnsworth A. Mucinous tumours. In: Surgical Pathology of the Ovaries. New York: Churchill Livingstone, 1997: 273.
- 47
Haney AF.
The pathogenesis and aetiology of endometriosis. In: EJ Thomas,
JA. Rock eds.
Modern Approaches to Endometriosis. Dordrecht: Kluwer, 1991: 3 19.
10.1007/978-94-011-3864-2_1 Google Scholar
- 48 Koninckx PR, Kennedy SH, Barlow DH. Endometriotic disease: the role of peritoneal fluid. Human Reprod. Update 1998; 4; 741 751.
- 49 Healy DL, Rogers PAW, Hii L, Wingfield M. Angiogenesis: a new theory for endometriosis. Human Reprod. Update 1998; 4; 736 40.
- 50 Oosterlynck DJ, Cornillie FJ, Waer M et al. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil. Steril. 1991; 56; 45 51.
- 51 Tseng JF, Ryan IP, Milam TD. Interleukin-6 secretion in vitro is upregulated in ectopic and eutopic endometrial stromal cells from women with endometriosis. J. Clin. Endocrinol. Metabolism 1996; 81; 1118 22.
- 52 Ota H, Igarashi S, Hatazawa J et al. Distribution of heat shock proteins in eutopic and ectopic endometrium in endometriosis and adenomyosis. Fertil. Steril. 1997; 68; 23 8.DOI: 10.1016/s0015-0282(97)81470-7
- 53 Jolicoeur C, Boutouil M, Drouin R et al. Increased expression of monocyte chemotactic protein-1 in the endometrium of women with endometriosis. Am. J. Pathology 1998; 152; 125 33.
- 54 Isaacson K, Galman M, Coutifaris C, Lyttle C. Endometrial synthesis and secretion of complement component-3 by patients with and without endometriosis. Fertil. Steril. 1990; 53; 836 41.
- 55 Leyendecker G, Kunz G, Noe M, Herbertz M, Mall G. Endometriosis: a disease and dysfunction of the archimetra. Human Reprod. Update 1998; 4; 752 62.
- 56 De la Cuesta RS, Eichorn JH, Rice LW et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol. Oncol. 1996; 60; 238 244.DOI: 10.1006/gyno.1996.0032
- 57 McMeekin DS, Burger RA, Manetta A et al. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol. Oncol. 1995; 59; 81 86.DOI: 10.1006/gyno.1995.1271
- 58 Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997; 30; 249 255.
- 59 Vercellini P, Parazzini F, Bolis G et al. Endometriosis and ovarian cancer. Am. J. Obstet. Gynecol. 1993; 169; 181 182.
- 60 Bell DA & Scully RE. Atypical and borderline endometrioid adenofibromas of the ovary. A report of 27 cases. Am. J. Surg. Pathol. 1985; 9; 205 214.
- 61 Snyder RR, Norris HJ, Tavassoli F. Endometrioid proliferative and low malignant potential tumours of the ovary. A clinicopathologic study of 46 cases. Am. J. Surg. Pathol. 1988; 12; 661 771.
- 62 Rosenblatt KA & Thomas D. Reduced risk of ovarian-cancer in women with a tubal-ligation or hysterectomy. Cancer Epidemiol Biomarkers Prev 1996; 5; 933 935.
- 63 Brinton LA, Gridley G, Persson I et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am. J. Obstet. Gynecol. 1997; 176; 572 579.
- 64 Nilbert M, Pejovic T, Mandahl N, Iosif S, Willens H, Mitelman F. Monoclonal origin of endometriotic cysts. Int. J. Gynaecol. Cancer 1995; 5; 61 63.
- 65 Jimbo H, Hitomi Y, Yoshikawa H et al. Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am. J. Pathol. 1997; 150; 1173 1178.
- 66 Tamura M, Fukaya T, Murakami T, Uehara S, Yajima A. Analysis of clonality in human endometriotic cysts based on evaluation of X chromosome inactivation in archival formalin-fixed, paraffin-embedded tissue. Lab. Invest. 1998; 78; 213 218.
- 67 Jiang X, Hitchcock A, Bryan EJ et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumour suppressor gene loci. Cancer Res. 1996; 56; 3534 3539.
- 68 Jiang X, Morland SJ, Hitchcock A et al. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res. 1998; 58; 1707 1712.
- 69 Czernobilsky B & Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet. Gynecol. 1979; 53; 318 323.
- 70 Fukunaga M & Ushigome S. Epithelial metaplastic changes in ovarian endometriosis. Mod. Pathol. 1998; 11; 784 788.
- 71 Ballouk F, Ross JS, Wolf BC. Ovarian endometriotic cysts: an analysis of cytologic atypia and DNA ploidy patterns. Am. J. Clin. Pathol. 1994; 102; 415 419.
- 72 Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumours. Cancer Res. 1998; 58; 2095 2097.
- 73 Salazar H, Godwin AK, Daly MB et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. 1996; 88; 1810 1820.
- 74 Stratton JF, Buckley CH, Lowe D, Ponder BAJ, the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. J. Natl. Cancer Inst. 1999; 91; 626 628.DOI: 10.1093/jnci/91.7.626